Iclusig ponatinib regulatory update

Australia’s Therapeutic Goods Administration ( TGA) approved Iclusig ponatinib from Ariad to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ariad plans to launch the pan- BCR-ABL tyrosine kinase inhibitor (TKI) in Australia in early 2015. ...